Article
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis.
Nature communications - 18 May 2021
Carr Ryan M, Vorobyev Denis, Lasho Terra, Marks David L, Tolosa Ezequiel J, Vedder Alexis, Almada Luciana L, Yurcheko Andrey, Padioleau Ismael, Alver Bonnie, Coltro Giacomo, Binder Moritz, Safgren Stephanie L, Horn Isaac, You Xiaona, Solary Eric, Balasis Maria E, Berger Kurt, Hiebert James, Witzig Thomas, Buradkar Ajinkya, Graf Temeida, Valent Peter, Mangaonkar Abhishek A, Robertson Keith D, Howard Matthew T, Kaufmann Scott H, Pin Christopher, Fernandez-Zapico Martin E, Geissler Klaus, Droin Nathalie, Padron Eric, Zhang Jing, Nikolaev Sergey, Patnaik Mrinal M
Abstract excerpt
Proliferative chronic myelomonocytic leukemia (pCMML), an aggressive CMML subtype, is associated with dismal outcomes. RAS pathway mutations, mainly NRASG12D, define the pCMML phenotype as demonstrated by our exome sequencing, progenitor colony assays and a Vav-Cre-NrasG12D mouse model. Further, these mutations promote CMML transformation to acute myeloid leukemia. Using a multiomics platform and biochemical and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.